|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AF10
|
|
gptkbp:bioavailability
|
100%
|
|
gptkbp:CASNumber
|
gptkb:142217-69-4
|
|
gptkbp:category
|
antiviral drug
antiviral
reverse transcriptase inhibitor
|
|
gptkbp:chemicalFormula
|
C12H15N5O3
|
|
gptkbp:contraindication
|
HIV infection without antiretroviral therapy
|
|
gptkbp:discoveredBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
antiviral drug
|
|
gptkbp:eliminationHalfLife
|
128–149 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1990s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
entecavir
|
|
gptkbp:KEGGID
|
D04047
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
reverse transcriptase inhibitor
|
|
gptkbp:MedlinePlusID
|
a605018
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
277.28 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
13%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1257
60750
54736
DB00442
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
lactic acidosis
liver enlargement
|
|
gptkbp:synonym
|
gptkb:Baraclude
|
|
gptkbp:UNII
|
Z9J8WYA0Y0
|
|
gptkbp:usedFor
|
gptkb:hepatitis_B
|
|
gptkbp:bfsParent
|
gptkb:Hepatitis_B
|
|
gptkbp:bfsLayer
|
5
|